Document:

Development and License Agreement

 Exhibit 10.1 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 A.P. PHARMA, INC. 
 and 
 MERIAL LIMITED 
  
  
 DEVELOPMENT AND LICENSE 
 AGREEMENT 
  
  

 CONTENTS 
  

							
	1	  	INTERPRETATION	  	2
		  	1.1	  	Definitions	  	2
		  	1.2	  	Construction	  	5
		  	1.3	  	Headings	  	6
			
	2	  	GRANT OF LICENSE AND OTHER RIGHTS	  	6
		  	2.1	  	Grant of License	  	6
			
	3	  	RESEARCH PROGRAM	  	7
		  	3.1	  	Implementation	  	7
		  	3.2	  	Reports and Data	  	9
			
	4	  	CONSIDERATION	  	9
		  	4.1	  	Program R&D Contract Services Fees and Costs	  	9
		  	4.2	  	License Fee	  	9
		  	4.3	  	Milestones	  	10
		  	4.4	  	Royalties	  	10
		  	4.5	  	Exchange Rate	  	10
			
	5	  	ACCOUNTS AND PAYMENT OF ROYALTIES	  	11
		  	5.1	  	Accounts and Records	  	11
		  	5.2	  	Statements and Payments	  	11
		  	5.3	  	Inspection and Audit	  	11
			
	6	  	MERIAL’S RESEARCH, DEVELOPMENT AND EXPLOITATION OBLIGATIONS	  	12
			
	7	  	TRIALS REQUIRED FOR REGULATORY APPROVAL	  	12
		  	7.1	  	Acknowledgment	  	12
		  	7.2	  	Merial’s Obligation	  	13
		  	7.3	  	Steering Committee	  	13
		  	7.4	  	Assistance from APP	  	13
			
	8	  	APP’S MATERIAL OBLIGATIONS	  	13
			
	9	  	IMPROVEMENTS	  	14
		  	9.1	  	Representations and Warranties	  	14
		  	9.2	  	Pre-Existing Intellectual Property	  	15
		  	9.3	  	Inventorship	  	15
		  	9.4	  	Notification of Improvements	  	15
		  	9.5	  	Ownership	  	15
		  	9.6	  	Filing, Prosecution and Maintenance of Patents on Improvements	  	15
		  	9.7	  	APP’s Obligations	  	15
			
	10	  	INFRINGEMENTS	  	15
		  	10.1	  	Obligation to Report	  	16
		  	10.2	  	Enforcement and Defense	  	16
		  	10.3	  	Patent Term Restoration	  	17
			
	11	  	TERM AND TERMINATION	  	17
		  	11.1	  	Term	  	17
		  	11.2	  	Termination by Merial Without Cause	  	17

  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

							
		  	11.3	  	Termination by Merial for Cause	  	17
		  	11.4	  	Termination by APP for Cause	  	18
		  	11.5	  	Termination for Change of Control	  	19
		  	11.6	  	Other Consequences of Termination	  	19
		  	11.7	  	Survival	  	19
			
	12	  	CONFIDENTIAL INFORMATION	  	20
		  	12.1	  	Definition	  	20
		  	12.2	  	General Obligations	  	20
			
	13	  	REGISTRATION OF THE LICENSED PRODUCT IN THE TERRITORY	  	22
		  	13.1	  	Ownership of Licensed Product Registration	  	22
		  	13.2	  	Additional Testing	  	22
		  	13.3	  	Contacts with the U.S. FDA and Other Regulatory Agencies	  	22
		  	13.4	  	APP’s Cooperation to Obtain and Maintain Registration	  	23
			
	14	  	LICENSED PRODUCT BRANDING	  	23
		  	14.1	  	APP Trademarks	  	23
		  	14.2	  	Merial Branding	  	23
			
	15	  	DISPUTE RESOLUTION	  	23
		  	15.1	  	Notice of Dispute	  	23
		  	15.2	  	Dispute Resolution	  	23
		  	15.3	  	Mediation	  	24
		  	15.4	  	Exchange of Information	  	24
		  	15.5	  	Legal Proceedings	  	24
			
	16	  	REPRESENTATIONS AND WARRANTIES	  	24
		  	16.1	  	Corporate Existence and Power	  	24
		  	16.2	  	Authority	  	25
		  	16.3	  	Absence of Litigation	  	25
		  	16.4	  	No Approvals or Consents Required	  	25
		  	16.5	  	Patents; Prior Art	  	25
		  	16.6	  	No Conflict	  	26
		  	16.7	  	No Prior Licenses	  	26
			
	17	  	INDEMNITY	  	26
		  	17.1	  	Indemnification by APP	  	26
		  	17.2	  	Indemnification By Merial	  	26
		  	17.3	  	Mechanics	  	27
			
	18	  	INSURANCE	  	27
			
	19	  	NOTICES	  	27
		  	19.1	  	General	  	27
		  	19.2	  	Particulars for Delivery of Notices	  	27
		  	19.3	  	After Hours Communications	  	28
		  	19.4	  	Process Service	  	29
			
	20	  	Force Majeure	  	29
			
	21	  	GENERAL	  	29
		  	21.1	  	Legal Costs	  	29
		  	21.2	  	Amendment	  	29

  

 (ii) 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

							
		  	21.3	  	Waiver and Exercise of Rights	  	29
		  	21.4	  	Rights Cumulative	  	30
		  	21.5	  	Further Steps	  	30
		  	21.6	  	Governing Law	  	30
		  	21.7	  	Assignment	  	30
		  	21.8	  	Liability	  	30
		  	21.9	  	Counterparts	  	30
		  	21.10	  	Entire Understanding	  	30
		  	21.11	  	Relationship of Parties	  	31
		  	21.12	  	Ethical Business Practices	  	31

  

 (iii) 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 THIS DEVELOPMENT AND LICENSE AGREEMENT (“Agreement”) is made effective September 4,
2009, by and between A.P. PHARMA, INC., a Delaware corporation with offices at 123 Saginaw Drive, Redwood City, CA 94063 USA (hereinafter “APP”), and MERIAL LIMITED, a company limited by shares registered in England
and Wales (registered number 3332751) with a registered office at P.O. Box 327, Sandringham House, Sandringham Avenue, Harlow Business Park, Harlow, Essex CM19 5TG England, and domesticated in Delaware, USA as Merial LLC, with a principal place of
business at 3239 Satellite Boulevard, Duluth, Georgia 30096 USA (“Merial”). References to Merial hereinafter shall include Merial’s Affiliates. 
 RECITALS 
  

	A	WHEREAS, APP has identified and owns certain rights, patents, technical information, formulations, processes, know-how, data, specifications, characterization
methods, characterization results, and other proprietary information relating to their Biochronomer semi-solid poly (ortho ester) drug delivery system, whether or not patented or patentable; and 

  

	B	WHEREAS, APP and Merial entered into a Research and Development Agreement, effective January 22, 2007, and as amended on December 10, 2007 and
May 20, 2008, to undertake the proof-of-concept phase (“POC Phase”) of a collaborative research program (“Program”) to produce and test a slow release [*] product using the Technology for dogs and cats;

  

	C	WHEREAS, APP and Merial substantially completed the POC Phase and now are prepared to undertake the full development phase of the Program (“FD Phase”);

  

	D	WHEREAS, Merial wishes to conduct additional clinical trials in relation to the Technology and the Licensed Product(s), to conduct, jointly with APP, other
development activities in relation to the Technology and Licensed Product, and 

  

	E	WHEREAS, the Parties have the capability, experience, and know-how to undertake their respective duties under the FD Phase; and 

  

	F	WHEREAS, Merial believes the Technology may have commercial application in the Field and wishes to exclusively Exploit the Licensed Product(s) in the Field in
the Territory, and Merial has the capability, experience, and know-how to Exploit the Licensed Product(s) in the Field in the Territory; and 

  

	G	WHEREAS, APP has agreed to grant a license to Merial to conduct such clinical trials and other development activities on the Licensed Product(s) and the
Technology and to Exploit the Licensed Product(s) in the Field in the Territory on the terms of this Agreement. 

 NOW,
THEREFORE, FOR AND IN CONSIDERATION OF THE PREMISES AND MUTUAL PROMISES, TERMS AND CONDITIONS HEREINAFTER SET FORTH, AND OTHER GOOD AND VALUABLE CONSIDERATION, THE RECEIPT AND SUFFICIENCY OF WHICH IS HEREBY ACKNOWLEDGED, THE PARTIES DO HEREBY AGREE
AS FOLLOWS: 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	1	INTERPRETATION 

  

	 	1.1	Definitions 

 As used in
this Agreement, the following defined terms shall have the following respective meanings: 
 “Affiliate” means
any corporation or business entity which controls, is controlled by or is under common control with a Party, where a corporation or business entity shall be deemed to control another corporation or business entity if it owns, directly or indirectly,
fifty percent (50%) or more of the securities or other ownership interests representing the equity, the voting stock or general partnership interest of such corporation or business entity. 
 “Agency” means any government regulatory entity in the United States (“U.S.”) or European Union (“E.U.”)
that reviews and grants product licenses for new animal health products. 
 “APP Background IP” means the
Intellectual Property Rights, particularly know-how, Patent, and copyrights, owned or licensed by APP and utilized in the performance of the Program which were in existence (as can be documented to Merial’s reasonable satisfaction or otherwise
demonstrated by competent proof in a court of law) prior to initiation of the Program. 
 “APP Know-How” means
(1) all ideas, technologies, and processes disclosed and claimed in the Patent and any related know-how, technologies, methodologies and processes made in the course of research by APP and (2) all ideas, concepts and information in any
form relating to the Patent, including trade secrets based thereon and any technical and other information, standards, procedures, methods, techniques, samples and advice, which has been developed or acquired by APP before the Commencement Date or
which is developed solely by APP or jointly by APP and Merial if it relates [*], during the course of the Program. 
 “APP Trademarks” means any registered and unregistered trademarks, trade names and logos that APP may grant Merial the right to use in relation to the Licensed Product from time to time. 
 “Biochronomer Technology” means bioerodible polymer compositions comprising poly (ortho esters) that may be prepared and
formulated to provide the controlled delivery of biologically active agents. Such compositions, their methods of preparation and their uses are covered in APP Background IP and APP Know How. 
 “Budget” means the budget set out in Exhibit B. 
 “Business Day” means a day which is not a Saturday, Sunday, or bank or federal holiday in Atlanta, Georgia, USA. 

“Change of Control” means a transaction or series of transactions the result of which is: 
  

	 	(a)	the transfer of ownership or voting control of more than 50% of the shares or ownership of APP if that transfer is to a competitor of Merial or

  

	 	(b)	 either Party sells or otherwise transfers all or substantially all of its assets other

  

 2 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
than by operation of law or through the licensing by APP of its key programs, including APF530. 

 For the sake of clarity, Change of Control does not include the refinancing of debt which does not result in either (a) or (b) above. 
 “Commencement Date” means the date specified in the preamble to this Agreement. 
 “Commercially Reasonable Efforts” means the level of efforts, resources and diligence, devoted in a sustained manner, that
would be typically devoted by a company in the business of developing and commercializing, as applicable, animal health products with similar or comparable commercial or market potential at a similar stage in their development or lifecycle stages,
similar or comparable profit potential and other relevant commercial, scientific and technical considerations reasonably and customarily taken into account in the industry. Such efforts, resources and diligence shall in no event be less than the
efforts that the party applies with respect to its other programs and products with similar commercial potential consistent with the exercise of good business judgment for the maximization of Licensed Product profits. Commercially Reasonable Efforts
requires that the Party, at a minimum: (a) promptly assign responsibility for such obligations to specific, qualified employee(s) who are held accountable for progress and monitor such progress on an ongoing basis; (b) set and consistently
seek to achieve specific and meaningful objectives for carrying out such obligations; and (c) consistently make and implement decisions and allocate resources designed to advance progress with respect to such objectives. 
 “Confidential Information” means any information specified in Clause 12. 
 “Exploit” means to develop, manufacture, have made, market, have marketed, hire, sell, have sold, license or otherwise
dispose of or use for commercial purposes, and “Exploitation” has a corresponding meaning. 
 “FD
Phase” means the phase set out in the third WHEREAS clause 
 “Field” means applications in dogs
and cats. 
 “Financial Year” means any 12-month period ending on 31 December and will include the period
between the Commencement Date and the next 31 December to occur. 
 “Improvement” means any and all
patentable or unpatentable improvements or enhancements to, modifications of, or developments or inventions arising from or based on the FD Phase during the term of this Agreement, including but not limited to patentable changes in specifications,
enhanced features, upgrades, design changes or revisions to the Technology. 
 “Intellectual Property Rights”
means all patent rights (including patent applications), copyrights (including future copyrights), trademarks, trade secrets, designs, and confidential and/or proprietary chemical substances, technical information, data and assays necessary or
useful to the FD Phase, trade, business or company names, or other proprietary rights, common law and equitable rights relating to Confidential Information. 
 “License” means the license specified in Clause 2.1. 
 “Licensed Product” means any product made, used, sold through or by means of the

  

 3 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
Technology licensed under this Agreement and incorporating [*] as the active ingredient which is intended for administration to a non-human animal. 
 “Licensed Rights” means the rights to employ the Technology solely within the Field, including the specific Patents
described, and any Improvement patents, divisions, continuations, continuations-in-part, and reissues of any patent that issues therefrom. 
 “Merial Background IP” means the Intellectual Property Rights, particularly know-how, patent rights, and copyrights, owned or licensed by Merial and utilized in the performance of the
Program which was in existence (as can be documented to APP’s satisfaction or otherwise demonstrated by competent proof in a court of law) prior to initiation of the Program. 
 “Merial Know-How” means all ideas, concepts and information in any form that Merial has relating to the development,
production, exploitation, and marketing of animal health products, including ideas, concepts, information, and trade secrets based thereon and any technical and other information, standards, procedures, methods, techniques, samples and advice,
including any such know-how in relation to manufacturing, which has been developed or acquired by Merial before the Commencement Date or which is developed solely by Merial or jointly by Merial and APP if it [*] during the course of the
Program 
 “Net Sales” means the net amount invoiced for sales of Licensed Product by Merial, its Affiliates,
licensees and assigns to non-affiliated third party customers following deductions from gross sales for items listed in (i) through (iv) below that either (a) [*], or (b) [*]: 
  

	 	(i)	[*]; 

  

	 	(ii)	[*]; 

  

	 	(iii)	[*]; and 

  

	 	(iv)	[*]. 

 Such amounts shall
be determined from Merial’s books and records maintained in accordance with US GAAP. For the avoidance of doubt, in no event shall Net Sales hereunder be construed to require Merial or it Affiliates to pay a Royalty on more than one
sale/transfer of the Licensed Product(s). 
 “Net Sales” shall not include a sale or transfer to an
Affiliate, licensee, or assignee, but the resale or transfer by such Affiliate, licensee or assign shall be included in the Net Sales. 
 “Party” or “Parties” means either Merial or APP or both, as the case may be. 
 “Patent” means the patents and patent applications listed on Exhibit A and (i) any re-examinations, revalidations, reissues, renewals, extensions, supplementing protection certificates and term restorations, any
confirmation patent or registration patent or patent of addition based on any such patent, and (ii) pending applications for patents including continuations, continuations in part, divisional, provisional, statutory registrations, utility
models, design patents, confirmations, revalidations, and substitute applications and inventors certificates, together with applicable foreign counterpart

  

 4 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
patens and patent applications, and all right to obtain patents and registrations with respect thereto. 
 “Person” means a natural person, a corporation, a partnership, a trust, a joint venture, a limited liability company, any governmental authority or any other entity or
organization. 
 “Program Data” means all data, results and all other data and information generated as a
result of the implementation of the Program. Program Data includes all XP files, XP reports, development reports, analytical methods, SOPs and instructions, and validation reports related to the Program. 
 “Program” means the collaborative development work which is based on Merial Know-How and APP Know-How and is described in
Exhibit “B”. 
 “Registrations” means such government approvals as are necessary to sell, promote or
distribute the Licensed Product(s) in the United States or in any other country in the Territory within which Merial in its sole discretion determines to Exploit the Licensed Product(s) in the Field in the Territory. 
 “Royalty” means the royalty calculated and payable in accordance with Clause 4.4, and “Royalties” has
a corresponding meaning. 
 “Task” means the separate tasks set out in Exhibit B. 
 “Technology” means the Patent and the APP Know-How, including Biochronomer Technology. 
 “Technology File” means the file specified in Clause 8.4. 
 “Term” means the period specified in Clause 11.1. 
 “Territory” means the world. 
 “U.S. FDA” means the Food and Drug Administration of the United States of America. 
 “Valid Claim” means a claim of an unexpired issued patent which shall not have been withdrawn, cancelled, or disclaimed, nor held unenforceable, unpatentable, or invalid by a
court, tribunal, arbitrator or government agency of competent jurisdiction in a final or unappealed or unappealable decision and which has not been admitted to be invalid or unenforceable through reissue or disclaimer. 
  

	 	1.2	Construction 

 Unless
expressed to the contrary, in this document: 
  

	 	(a)	words in the singular include the plural and vice versa; 

  

	 	(b)	any gender includes the other genders; 

  

	 	(c)	if a word or phrase is defined its other grammatical forms have corresponding meanings; 

  

 5 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	(d)	“includes” means includes without limitation; 

  

	 	(e)	no rule of construction will apply to a clause to the disadvantage of a party merely because that party put forward the clause or would otherwise benefit from it;

  

	 	(f)	a reference to: 

  

	 	(i)	a person includes a natural person, partnership, joint venture, unincorporated association, corporation, a limited liability company, any government or statutory body
or authority, or any other entity or organization; 

  

	 	(ii)	a person includes the person’s legal personal representatives, successors, assigns and persons substituted by novation; 

  

	 	(iii)	time is to local time in New York, N.Y; 

  

	 	(iv)	“$” or “dollars” is a reference to United States currency; 

  

	 	(v)	writing includes any mode of representing or reproducing words in tangible and permanently visible form, and includes fax and e-mail transmissions;

  

	 	(vi)	this Agreement includes all schedules and exhibits to it; and 

  

	 	(vii)	a clause, schedule or exhibit is a reference to a clause, schedule or exhibit, as the case may be, of this Agreement; 

  

	 	(g)	if the date on or by which any act must be done under this document is not a Business Day, the act must be done on or by the next Business Day; and

  

	 	(h)	where time is to be calculated by reference to a day or event, that day or the day of that event is excluded. 

  

	 	1.3	Headings 

 Headings do not
affect the interpretation of this document. 
  

	2	GRANT OF LICENSE AND OTHER RIGHTS 

  

	 	2.1	Grant of License 

  

	 	(a)	Subject to the terms and conditions of this Agreement, for the term of the Agreement, APP hereby grants to Merial an exclusive, sub-licensable license to APP’s
rights in the Technology and the Improvements (i) to Exploit Licensed Products in the Field in the Territory and (ii) to conduct such clinical and laboratory trials and other research and development activities in relation to the
Technology and the Licensed Product(s), as set forth in the Program, in order to make the Licensed Product(s) and to enable Merial to obtain all appropriate approvals and Registration(s) of the Licensed Product(s) necessary to permit full
Exploitation in the Field in the Territory (“License”). 

  

	 	(b)	 Merial shall have the right to sub-license its License in the

  

 6 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
Field. [*] Merial shall include this expected royalty in any terms negotiated with the sub-licensee. 

  

	3	RESEARCH PROGRAM 

  

	 	3.1	Implementation 

  

	 	(a)	The Parties agree to use Commercially Reasonable Efforts to undertake the FD Phase of the Program, as drafted and as reasonably modified by agreement of the Parties. As
of the signing of this Agreement based on the information known to date, APP believes that the Tasks will be completed according to the timelines set out in Exhibit B. Promptly after, but no later than after [*] business days, APP becomes
aware of any matter (including but not limited to an event, change or issue, technical or otherwise) that could have an adverse impact on the Program’s timeline, APP will bring such matter to the attention of Merial’s technical lead on the
Steering Committee for consideration. The timelines can be adjusted only by written agreement of the Parties and only if the Parties have mutually identified and agreed to such adjustment in a writing signed by both Parties. APP does not covenant or
warrant any research results or achievement of milestones and expressly disclaims any such warranties, express or implied. 

  

	 	(b)	The Parties agree to undertake the Program set out in Exhibit B to this Agreement for the Budget set forth in such exhibit. Promptly after APP becomes aware of any
matter (including but not limited to an event, change or issue, technical or otherwise) that could have an adverse impact on the Budget ascribed to any task, APP will bring such matter to the attention of the Steering Committee for consideration.
The Budget can be adjusted only by written agreement of the Parties and only if the Parties have mutually identified and agreed to such adjustment in a writing signed by both Parties. [*] APP will submit an invoice for services performed in
the prior [*]. The invoice [*] will both be broken out by separate Tasks, the hours spent, [*], as the case may be in [*] Task in the relevant time period covered by the invoice [*] Task in the relevant time
period, and the [*] in the relevant time period, and [*] through the time period covered by the invoice. If no written objection from Merial is received by APP within [*] business days of Merial’s receipt of the anticipated
work schedule, [*]. If Merial submits a written objection to Tasks identified in [*] work schedule, APP can proceed with the Tasks scheduled for the [*], provided APP has not made any changes to those Tasks from the most recent
[*] schedule of work which APP provided [*], and the parties will use their best efforts to resolve Merial’s objection(s) within [*]. Notwithstanding the foregoing, APP shall be entitled to submit to Merial an invoice for
documented costs incurred by APP in the course of performing Tasks conducted [*] in connection with the Program and as consistent with the Budget and Exhibit C within [*], and Merial shall reimburse APP for such costs incurred in
connection with such Tasks within [*] days after receiving such invoice. 

  

	 	(c)	 APP shall use its Commercially Reasonable Efforts to supply Merial with all required materials, [*], to allow Merial to conduct all applicable
studies and evaluations needed to complete Agency license applications, as well as to complete product license applications for other countries. APP will provide reasonable technical assistance and advice, consultation, opinion papers, reviews,
white papers, research protocols, pertinent data and data interpretation, results, and information to Merial related to the Technology reasonably available to it and

  

 7 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
any newly produced research within any of the Licensed Rights conducted by its employees or its agents in the conduct of clinical and laboratory trials, registrations and related work. Merial
shall pay APP for the provision of such services, information, assistance and advice in accordance with Clause 4.1 below. 

  

	 	(d)	Both Parties will carry out the work associated with the Program in accordance with the highest academic and professional standards. Furthermore, the Parties shall use
[*] to achieve the degree of reliability and accuracy that is appropriate and accepted within the industry for work of this kind. APP and Merial each represents that it has the requisite expertise, ability and legal right to render the work
and will perform the work in an efficient and ethical manner. Both Parties will abide by all laws, rules and regulations that apply to the performance of the work. 

  

	 	(e)	Unless otherwise specified in this Agreement or its Appendices and subject to the terms of Article 4, each Party shall provide the personnel, offices, laboratory
facilities, animals, animal housing, equipment, field space, utilities, techniques, reagents, and other supplies as needed by that Party for the performance of that Party’s responsibilities under the Program. All equipment purchased and paid
for by either Party from its own funds, and for which they are not reimbursed by the other Party, for the performance of the Program shall be the property of that Party. 

  

	 	(f)	The Parties recognize and acknowledge that APP contemplates using the services of contract manufacturing and analytical organizations for the FD Phase of the Program,
and, further, that if the Parties agree that APP is to carry out research and development work [*], APP would do so through a contract research organization. All third parties hired by APP to perform some or all of the research contemplated
hereunder must be approved in writing by Merial prior to the third party beginning work which approval may not be unreasonably withheld, except APP may, without Merial’s consent, hire an individual(s) to perform R&D contract services under
the Agreement at APP’s facilities under the supervision of APP personnel. 

  

	 	(g)	In an effort to minimize the cost-of-goods associated with the Licensed Product(s), the Parties agree to work collaboratively during the FD Phase to optimize the
sourcing and procurement of the License Product components and the methods and/or site of manufacture. The selection of third parties for procurement and manufacture requires the written consent of both Parties, such consent not to be unreasonably
withheld. 

  

	 	(h)	Merial shall be allowed to use and register its own trademarks for any of the Licensed Products, and any such trademarks shall be the exclusive property of Merial.
Responsibility for trademark registrations in the Territory, as well as the expenses associated with such registration(s), will be borne exclusively by Merial. 

  

	 	(i)	Merial will at all times recognize the validity of any licensed trademarks owned, used by, or licensed to APP and will undertake no actions to dilute the value of such
trademarks 

  

	 	(j)	 APP will at all times recognize the validity of any licensed trademarks owned, used by, or licensed to Merial and will undertake no actions to dilute
the value of

  

 8 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
such trademarks. 

  

	 	3.2	Reports and Data 

  

	 	(a)	All data and reports regarding the Program data shall be treated as confidential information in accordance with Article 12 of this Agreement. Each Party shall
record all Program Data. [*]. Merial shall have full access to and use of all Program Data, [*], as needed for Merial to exercise the rights granted to it under this Agreement. 

  

	 	(b)	APP shall record all Program Data APP generates in XP files, and the XP files shall contain full details and information on all tests carried out, procedures used, and
other data and information generated, whether successful or not. [*]. 

  

	 	(c)	APP will [*] during the FD Phase. APP and its Affiliates and licensees shall [*] provided at least one of the following conditions has been met:
(i) [*]; (ii) [*]; (iii) [*]; (iv) [*]; (v) [*], or (vi) [*]. The Parties shall attempt to resolve all disputes, controversies or differences which may arise between the Parties
hereto, out of or in relation to or in connection with this Clause through discussions held between the heads of Research and Development of the respective Parties, and if after [*] the dispute remains unresolved, the dispute shall be
resolved in accordance with Article 15. 

  

	 	(d)	APP agrees to make reasonable modifications [*] in the event [*] take other appropriate action to protect its intellectual property rights.

  

	 	(e)	Where useful for development and registration of a Licensed Product in the Field, APP shall provide Merial with [*], provided that APP is not under an obligation
to a third party to keep such data confidential, in which event APP will use reasonable efforts to obtain the consent of the third party to release the information to Merial. 

  

	 	(f)	During the Term, APP can request, on behalf of itself and/or its Affiliates and licensees, [*]. 

  

	4	CONSIDERATION 

  

	 	4.1	Program R&D Contract Services Fees and Costs 

 In order to implement the Program, Merial shall, upon execution of this Agreement by both parties and receipt of an invoice from APP, [*], as set forth in Exhibit B. Then going forward, Merial
shall [*]. For clarity, APP shall have the right to subcontract out the performance of R&D contract services by APP, subject to Section 3.1(f), and such services shall [*]. The total budget cannot [*]. APP can
[*], and APP must receive [*]. APP can [*]. The parties expressly acknowledge that they agree for [*] the costs of individual purchases of materials or other consumables or the fees and expenses of agreed-upon third party
expenditures which are outside of the budget [*]. APP shall invoice Merial [*], and payment shall be due within [*] of receipt of APP’s invoice by Merial. [*]. 
  

	 	4.2	License Fee 

 In
consideration of the license and other rights granted to Merial under this Agreement by

  

 9 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
APP, Merial agrees to pay to APP by electronic funds transfer to a bank account nominated by APP in writing [*] dollars) upon receipt of a fully executed original of this Agreement and an
invoice from APP. 
  

	 	4.3	Milestones 

 In partial
consideration for APP conducting work under the FD Phase, Merial agrees to pay APP by electronic funds transfer to a bank account nominated by APP in writing the following non-refundable amounts at the defined milestones described below: 

 

	 	(a)	[*] dollars) within [*] of the [*] for [*] and Merial’s receipt of an invoice from APP; and 

  

	 	(b)	[*] dollars) within [*] of the [*] and Merial’s receipt of an invoice from APP. 

  

	 	4.4	Royalties 

 In addition to
the license fees specified in Clause 4.2 and as partial consideration for the license and other rights granted to Merial hereunder, Merial agrees to pay to APP a Royalty on the Net Sales of Licensed Product during the Term of this Agreement
[*] as follows: 
  

	 	(a)	in the jurisdictions of the Territory [*]: 

  

	 	(i)	[*] of the portion of Net Sales less than and including [*] in a Financial Year; 

  

	 	(ii)	[*] of the portion of Net Sales greater than [*] but equal to or less than [*] in a Financial Year; and 

  

	 	(iii)	[*] of the portion of Net Sales greater than [*] in a Financial Year. 

  

	 	(b)	In the jurisdiction(s) of the Territory [*], would be: 

  

	 	(i)	[*] of the portion of Net Sales less than and including [*] in a Financial Year; 

  

	 	(ii)	[*] of the portion of Net Sales greater than [*] but equal to or less than [*] in a Financial Year; and 

  

	 	(iii)	[*] of the portion of Net Sales greater than [*] in a Financial Year. 

  

	 	(c)	In the event that Merial, [*]. Merial’s royalty obligation to APP on Net Sales in any given country or market, [*]. 

  

	 	(d)	In addition, APP will be entitled to receive from Merial [*], payment to be made within [*] from receipt by Merial. 

  

	 	4.5	Exchange Rate 

 All
payments due under this Agreement shall be paid to APP in United States currency in New York, NY, or at such other place as APP may reasonably designate consistent with the laws and regulations controlling in any foreign country, but not in any
other currency. When Licensed Products are sold by Merial and its Affiliates or sublicensees

  

 10 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
for monies other than United States dollars, the sales shall be converted to equivalent United States dollars on a monthly basis, and then the earned Royalties will be determined on that amount.
The exchange rate will be the monthly periodic average rate that [*]. Merial will include the exchange rate [*] in the statements described in Section 5.2. 
  

	5	ACCOUNTS AND PAYMENT OF ROYALTIES 

  

	 	5.1	Accounts and Records 

 Throughout the Term, Merial must keep, in accordance with US generally accepted accounting practices (“US GAAP”), true and accurate accounts and records of all Net Sales and all other matters necessary to enable calculation of the
Royalties payable to APP under Clause 4.4. 
  

	 	5.2	Statements and Payments 

 Within [*] after the close of each calendar quarter of the Financial Year (i.e. the last day of the months of March, June, September and December) in which Merial makes the first commercial sale of a Licensed Product in the
Territory, and within [*] after the end of each subsequent quarter, Merial shall: 
  

	 	(a)	provide to APP a statement: 

  

	 	(i)	specifying all Net Sales of the Licensed Product(s) [*] during that quarter or, if there were no sales and/or no Net Sales during that quarter , a statement to
that effect; and 

  

	 	(ii)	showing the calculation of the Royalties payable to APP for that quarter [*]; and 

  

	 	(b)	pay by electronic funds transfer into the bank account nominated by APP in writing the Royalties due to APP under Clause 4.4 for that quarter.

  

	 	(c)	Additionally, if applicable laws or regulations require the withholding of taxes, the taxes will be deducted by Merial from the Royalty Payments and remitted by Merial
to the proper tax authority. Proof of payment shall be provided to APP within sixty (60) days after payment. Merial will cooperate in pursuing the refund of such tax, if such refund is appropriate in APP’s determination.

  

	 	5.3	Inspection and Audit 

  

	 	5.3.1	 No more than [*] and on at least [*] prior written request by APP and confirmed by Merial, Merial shall allow an independent certified
public accounting firm in the United States, selected by APP and reasonably acceptable to Merial, to inspect and audit during normal business hours the accounts and records kept by Merial under Clause 5.1, as may be reasonably necessary
for the purposes of verifying the accuracy of Merial’s Royalty statement and Royalty calculation, pursuant to Clauses 4.4 and 5.2, respectively, for any quarter or Financial Year ending not more than [*] months prior to the
date of such requests. Such accounting firm may only disclose to APP information relating to the accuracy or inaccuracy of the Royalty statements and Royalty calculation hereunder. APP and/or APP’s accountant shall not disclose the contents to
any third party without the prior

  

 11 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
written consent of Merial except as required by government agencies or other bodies that have the statutory or regulatory authority to receive such information. Merial shall have the right to
inspect any audit reports derived from any such audit. 

  

	 	5.3.2	Where, as a result of such an inspection or audit, it is discovered that the accounts and records are inaccurate or the Royalties paid differ from the Royalties payable
under Clause 4.4, such difference, payments or adjustments shall be made to the other Party to address such inaccuracy or differences within [*] after the inspection or audit report revealing the inaccuracy. APP shall pay any and
all costs and expenses associated with the inspection and audit of Merial’s records, unless a difference, favorable to APP, between the Royalties paid and the Royalties payable exists and exceeds [*] of the payable Royalties for the
period under audit, in which case Merial shall pay for the cost and expenses associated with that inspection. 

  

	 	5.3.5	Upon expiration of [*] following the end of any Financial Year , the calculation of Royalties payable with respect to such Financial Year shall be binding and
conclusive upon APP, and Merial shall be released from any liability or accountability with respect to Royalties for such Financial Year. [*]. 

  

	6	MERIAL’S RESEARCH, DEVELOPMENT AND EXPLOITATION OBLIGATIONS 

  

	 	(a)	Subject to Clause 6(b), Merial shall use Commercially Reasonable Efforts to Exploit the Licensed Product(s) in the Field in the Territory, as soon as
practicable, consistent with sound and reasonable business practices and judgment, as applied to the current market and as permitted by this Agreement. 

  

	 	(b)	Merial shall use Commercially Reasonable Efforts to obtain and maintain [*] all necessary government or other permits, approvals, consents, certifications,
authorizations and Registrations necessary to Exploit the Licensed Product(s) under this agreement in the Field in the Territory. 

  

	 	(c)	Merial shall use Commercially Reasonable Efforts to obtain and comply with all Registrations obtained and all applicable laws in Exploiting the Licensed Product(s) in
the Field in the Territory under this Agreement. 

  

	 	(d)	Merial shall undertake its obligations under the FD Phase of the Program that will include potential use of the Licensed Product(s) for the treatment of pain in cats
and dogs in the Field. The implementation of the Program will provide a better opportunity for Merial to maximize the value of the Licensed Product(s) and the amount of Royalties to be paid to APP. Both Parties, however, understand and acknowledge
the vagaries inherent in clinical trials and of the regulatory environment and agree that the Program cannot produce guaranteed financial results. 

  

	7	TRIALS REQUIRED FOR REGULATORY APPROVAL 

  

	 	7.1	Acknowledgment 

 The
Parties acknowledge that, as at the Commencement Date, the Technology, and Licensed Product do not have regulatory approval in the Territory and that further clinical trials in relation to the Technology and Licensed Product are required in order to
apply

  

 12 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
and be granted such regulatory approval in the Territory. The Parties agree to cooperate with each other in regard to all technical assistance and documentation regarding the Licensed Rights and
the requirements to obtain Agency licenses for the Licensed Product(s). 
  

	 	7.2	Merial’s Obligation 

 Merial, using the Merial Know-How, shall conduct clinical and laboratory trials in relation to the Technology and the Licensed Product(s), as permitted by this Agreement, and as may be necessary to obtain and maintain all Registrations,
[*], Merial may employ third parties to conduct some or all of these tests. The draft reports of all such trials [*]. Such draft reports shall be considered Merial’s Confidential Information and treated in accordance with
Article 12. 
  

	 	7.3	Steering Committee 

  

	 	(a)	The Parties shall, as soon as practicable after the Commencement Date, form a Steering Committee comprising [*] nominated by Merial and [*] nominated by
APP to oversee and make recommendations in relation to the clinical and laboratory trials conducted by Merial under this Article 7. In addition to these [*] members, a Merial employee responsible for managing and protecting
Merial’s intellectual property shall be entitled to attend the Steering Committee meetings in order to ensure timely patent filings. 

  

	 	(b)	The Steering Committee shall meet semi-annually face-to-face or by telephone or other electronic means. Until Merial has obtained regulatory approval of a Licensed
Product and if the Steering Committee meets face-to-face, every second face-to-face meeting will be held at APP’s premises, unless the Steering Committee determines otherwise. 

  

	 	(c)	The Steering Committee will decide in good faith and based upon the best available scientific and technical practices and results when the tasks of the FD Phase of the
Program should be launched and when the deliverables are achieved. 

  

	 	7.4	Assistance from APP 

 In
addition to participation on the Steering Committee, and prior to obtaining Registrations for the Licensed Product(s) filed by Merial, APP shall, upon Merial’s reasonable request, provide or cause to be provided, as may be available to APP, any
consultation, opinion papers, reviews, white papers, research protocols, data interpretation, expert opinions, and/or technical assistance and advice in the conduct of its clinical and laboratory trials and related work under Clause 7.2.
Merial will reimburse reasonable and documented expenses incurred by APP specifically linked to the preparation or delivery of the requested work, including costs of materials, animal per diem costs, and lab test expenses, if the expenses are
approved in advance in writing by an authorized representative of Merial. If the expenses are not so approved, APP shall have no obligation to incur them. 
  

	8	APP’S MATERIAL OBLIGATIONS 

 APP acknowledges and agrees that in order for Merial to be able to meet its obligations to obtain Registration(s) for the Licensed Product(s) and to Exploit the Licensed Product(s)

  

 13 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
in the Field in the Territory, APP must provide certain assistance and comply with certain obligations, and that compliance with these obligations is partial consideration for the Royalty payment
made hereunder (“APP Material Obligations”). For purposes of this Agreement, APP Material Obligations shall include the following obligations of APP: 
  

	 	(a)	undertaking its responsibilities under the FD Phase of the Program; 

  

	 	(b)	transferring APP Know-How and all information related to research and development of Licensed Product not already transferred to Merial within thirty (30) days of
execution of the Agreement; 

  

	 	(c)	transferring APP Know-How and all information necessary to file for approval of the Licensed Product(s) with the U.S. FDA or other applicable regulatory agency,
including manufacturing know-how as required; 

  

	 	(d)	provision of technical support to Merial during the FD Phase and registration of Licensed Product, as set forth in Article 7 above, upon Merial’s written request.
Merial will pay reasonable and documented expenses incurred by APP specifically linked to the provision of such technical support If the expenses are not so approved, APP shall have no obligation to incur them; and 

  

	 	(e)	[*]. Merial shall be entitled [*] upon (i) any commencement of a bankruptcy proceeding by or against APP which has not been dismissed within ninety
(90) days, upon Merial’s written request therefor, unless APP or a party designated by APP elects to continue to perform, and has the ability to so perform, all of its obligations hereunder, or (ii) if not delivered under
(i) above, following the final rejection of this Agreement by or on behalf of APP in such bankruptcy proceeding and in accordance with applicable law, upon Merial’s written request therefor. 

  

	9	IMPROVEMENTS 

  

	 	9.1	Representations and Warranties 

 9.1.1 Except as each Party has otherwise advised the other Party in writing prior to the Commencement Date, each Party represents and warrants to the other Party that as of the Commencement Date,
(a) it has sufficient legal and/or beneficial title and ownership under its Intellectual Property rights necessary for it to fulfill its obligations under this Agreement and to grant any rights thereto, including the right to grant a license
thereto; and (b) to the best of its knowledge, there is no material unauthorized use, infringement, or misappropriation of any of its Intellectual Property rights by third parties relevant to the Program or other rights granted under this
Agreement. 
 9.1.2 APP represents and warrants that to the extent permitted by applicable law each of its
employees has entered into an agreement with APP that provides for the assignment to APP of all inventions made by such employee during the course of the employee’s employment with APP. 
 9.1.3 Merial represents and warrants that to the extent permitted by applicable law each of its employees has entered into an
agreement with Merial that provides for the assignment to Merial of all inventions made by such employee during the course of the employee’s employment with Merial. 
  

 14 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	9.2	Pre-Existing Intellectual Property 

 Background IP owned by or licensed to either Party prior to the execution of this Agreement shall remain the exclusive property of that Party. 
  

	 	9.3	Inventorship 

 Inventorship of Improvements shall be determined in accordance with United States Patent law. 
  

	 	9.4	Notification of Improvements 

 If at any time during the Term either Party becomes possessed of any Improvement (whether patentable or not), it must [*] days from such event communicate that Improvement to the other Party providing full particulars. 
  

	 	9.5	Ownership 

 Any
Improvement which relates [*] and those which are made [*] shall [*]. Any Improvement which relates [*] and those which are made [*] shall be [*]. All other Improvements shall be [*]. Notwithstanding
the other provisions of this Clause, Improvements which relate solely to [*], whereas Improvements which relate solely to [*]. 
  

	 	9.6	Filing, Prosecution and Maintenance of Patents on Improvements 

  

	 	9.6.1	Merial shall have the right, but not the obligation, to (in its sole discretion and at its own cost) file, prosecute, and maintain where so filed in the Territory any
patent applications and patent(s) [*] and on the Licensed Product(s), including conducting any interferences, reissues, examinations, oppositions, nullity proceedings and any similar proceedings. [*]. If [*] agrees to grant and
hereby does grant [*] the right to so proceed separately [*] and to have [*] such other terms as are mutually agreed upon by the Parties. Both Parties shall keep the other advised of the status of actual and prospective patent
filings and upon request, provide advanced copies of any papers related to such filings, prosecutions, and maintenance of such patent filings. With respect to all filings hereunder, [*] related to such filings, prosecutions, and maintenance.

  

	 	9.6.2	If [*] files a patent application in its own name for [*] to grant and hereby does grant to [*]. If [*] otherwise owns an Improvement [*]
agrees to grant and hereby does grant [*]. 

  

	 	9.6.3	Merial acknowledges ownership of the Technology by APP and does not represent that it has any ownership rights in the Technology. 

  

	 	9.7	APP’s Obligations 

 APP shall provide such necessary and reasonable assistance as Merial may reasonably request in the [*]. 
  

	10	INFRINGEMENTS 

  

 15 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	10.1	Obligation to Report 

 Each Party must promptly report in writing to the other: 
  

	 	(a)	any actual or suspected infringement by a third party of any Patents or other Intellectual Property Rights subsisting in the Improvements, Licensed Product or the
Technology; and 

  

	 	(b)	any allegation or claim by a third party of invalidity or unenforceability of the Patents or other Intellectual Property Rights in the Technology, the Improvements, or
the Licensed Product(s) or that the Patents or other Intellectual Property Rights in the Technology, the Improvements, or the Licensed Product(s) infringe(s) that third party’s rights. 

  

	 	10.2	Enforcement and Defense 

  

	 	(a)	[*], shall have the first right to initiate and prosecute such legal action in the Field at its own expense (either in its own name or in the name of both
Parties) or to control any Opposition or Re-examination Proceeding or declaratory judgment action relating to the Patents, the Improvements, and the Technology, as they relate to the Licensed Product(s) in the Field. [*], to either initiate
and prosecute such action or to control any Opposition or Re-examination Proceeding or such declaratory judgment action. [*] after the date of notice of infringement, [*] have the right to bring suit. In any legal action, the
non-initiating Party shall have the right, at its expense, to be represented by legal counsel of its choice. 

  

	 	(b)	For any action to terminate any infringement of Patent or any misappropriation or misuse of Technology, in the event that either Party is unable to initiate or
prosecute such action solely in its own name, the other Party will join such action voluntarily and will execute and cause its sublicensees to execute all documents necessary for the other Party to initiate litigation to prosecute and maintain such
action. In connection with any action, both Parties will cooperate fully and will provide each other with any information or assistance that either may reasonably request. Each Party shall keep the other informed of the developments in any action or
proceeding, including, to the extent permissible by law, the status of any settlement negotiations and the terms of any offer related thereto. 

  

	 	(c)	[*] to settle any such legal action by granting a sublicense under the Technology to the Licensed Product(s) in the Field. [*] to settle any such legal
action by granting a sublicense under the Technology to the Licensed Product(s) in the Field [*] provided that such sublicense complies with Section 2.1(b). Except as otherwise provided herein, neither Party shall have the right to
settle any legal action by granting a sublicense under the Technology for the Licensed Product(s) in the Field without the consent of the other Party, which shall not be unreasonably withheld. 

  

	 	(d)	Any recovery obtained by either or both Parties in connection with or as a result of any action contemplated by this Article 10, whether by settlement or
otherwise, shall be shared in order as follows: 

  

	 	(i)	[*] costs and expenses incurred in connection with the action; 

  

 16 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	(ii)	[*] costs and expenses incurred in connection with the action; and 

  

	 	(iii)	the Parties shall be compensated from the balance of the recovery [*]. 

  

	 	(e)	If, as a result of any final, unappealable or unappealed legal action, the Patents or other Intellectual Property Rights in the Technology or the Licensed Product(s)
are deemed invalid or unenforceable or a determination is made that the Patents or other Intellectual Property Rights in the Technology or the Licensed Product(s) infringes a third party’s rights, [*]. 

  

	 	10.3	Patent Term Restoration 

 The Parties hereto shall cooperate with each other in obtaining patent term restoration or supplemental protection certificates or their equivalents in any country in the Territory where applicable to the Patents. In the event that
elections with respect to obtaining such patent term restoration are to be made, the patent owner shall have the right to make the election and the other Party agrees to abide by such election. 
  

	11	TERM AND TERMINATION 

  

	 	11.1	Term 

  

	 	(a)	The term of the Program shall begin upon the Commencement Date and, unless sooner terminated as hereinafter provided, shall continue in full force and effect through
the filing of the first NADA [*] or the [*] anniversary of the Commencement Date whichever comes first (“Term”). 

  

	 	(b)	The term of the license granted by APP to Merial according to Clause 2.1 shall begin upon the Commencement Date and, subject to earlier termination in accordance
with its provisions, will continue until the date of expiry of the last Patent. 

  

	 	11.2	Termination by Merial Without Cause 

 During the FD Phase, Merial may terminate this agreement for any reason on ninety (90) days prior written notice to APP. Once a Licensed Product has been sold, Merial may terminate the agreement for
any reason on six (6) months prior written notice to APP. Notwithstanding the preceding, Merial shall not terminate this Agreement per this clause, within six (6) months following the Commencement Date. 
  

	 	11.3	Termination by Merial for Cause 

  

	 	(a)	Merial may terminate this Agreement immediately on written notice to APP if APP: 

  

	 	(i)	is in material breach of any of APP Material Obligations and fails to rectify such breach within sixty (60) days after receipt of written notice from Merial
specifying the breach; or 

  

	 	(ii)	 during the FD Phase, is or becomes insolvent, is unable to pay its debts as and when they become due, ceases to carry on business, or

  

 17 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
proceedings are commenced, and not dismissed [*] after notice to APP, to have it wound up or a receiver and manager (or other administrator) is appointed to all or any part of its assets
and undertakings. 

  

	 	(b)	For the purposes of this Clause 11.3, APP Material Obligations are limited to the APP Obligations set forth in the following Articles and Clauses: 2,
3, 4.1, 7.1, 7.3, 7.4, 8, 9.5, 9.7, 10, 12, 13, 14.1, 17.1 and 18 and Exhibit B. 

  

	 	11.4	Termination by APP for Cause 

  

	 	(a)	APP may terminate this Agreement immediately on written notice to Merial if Merial: 

  

	 	(i)	upon sixty (60) days prior written notice to Merial if Merial has either not filed an administrative NADA for a Licensed Product within [*] of the
Commencement Date or not commercialized a Licensed Product within [*] of receiving approval of the administrative NADA and assignment of a NADA number from the U.S. FDA; 

  

	 	(ii)	is in material breach of any of the Merial Material Obligations under this agreement and fails to rectify such breach within sixty (60) days after receipt of
written notice from APP specifying the breach; or 

  

	 	(ii)	is or becomes insolvent, ceases to carry on business, or proceedings are commenced to have it wound up or a receiver and manager (or other administrator) is appointed
to all or any part of its assets and undertakings. 

  

	 	(b)	For the purposes of this Clause 11.4, Merial’s Material Obligations under this Agreement are limited to those set forth in the following Articles and
Clauses: 3, 4, 5, 6, 7.1, 7.2, 7.3, 9.5, 9.6, 10, 12, 13, 17.2, and 18, and Exhibit B. 

  

 18 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	11.5	Termination for Change of Control 

 If there is a Change in Control of a party, that party must notify the other party in writing on or before the date the Change of Control takes effect. The other party may then, within three (3) months after receiving such notice of
Change of Control, terminate this agreement on twelve (12) months’ notice to the first party. 
  

	 	11.6	Other Consequences of Termination 

 On the expiry or termination of this Agreement for any reason, and without limiting the parties’ other obligations on termination specified in this Article 11: 
  

	 	(a)	Merial must pay to APP within [*] after the effective date of termination all Royalties and license fees due and owing up to the effective date of termination;

  

	 	(b)	Merial may complete the manufacture or provision of any Licensed Products in accordance with any contract it has entered into with any third party in respect of such
Licensed Products, not to exceed [*] from the date of termination or expiration, and may sell its existing stocks of Licensed Products provided it complies with its obligations to pay Royalties in accordance with Article 4 and provide
statements in accordance with Article 5; 

  

	 	(c)	Merial must cease using the Technology other than as necessary under this Clause 11.6; and 

  

	 	(d)	Merial must promptly return to APP all materials, technical data and any other information (including APP Know-How) supplied to Merial by APP, and all copies of such
materials in Merial’s possession, power or custody; 

  

	 	(e)	If termination is by APP for cause or by Merial without cause, [*], including termination of any third-party contracts, disposal of raw materials and work
relating to the Program actually performed as of the time of termination [*]; 

  

	 	(f)	If termination is by Merial for cause under Clause 11.3(a), [*]. For the sake of clarity, Merial shall retain all of its rights to bring an action against
APP for any other damages and any other remedy in law or equity; and 

  

	 	(g)	If a Licensed Product(s) has been launched by Merial prior to termination for any reason except for termination for cause by Merial and Merial is interested in
licensing its rights in the Licensed Product(s) and the Improvements to another party, APP shall have a first right of negotiation to acquire a license, on commercially reasonable terms negotiated in good faith, to Exploit in the Field in the
Territory Merial’s rights in the Licensed Product(s) and the Improvements. 

  

	 	11.7	Survival 

 The provisions
of Articles 9, 10, 11, 12, 14, 15, 16, and 17 shall survive the termination or expiry of this Agreement. In the event that a third party acquires substantially all of the assets of either Party, the third party shall be bound by the terms of
this Agreement through the remaining term. All rights, options, assignments, and licenses granted under or pursuant to this Agreement by either Party are, and will otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy
Code, licenses of right to “intellectual property” as defined under Section 101 of the U.S.

  

 19 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
Bankruptcy Code. The Parties agree that Merial, as licensee of such rights under this Agreement, will retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code.
The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code which has not been dismissed within ninety (90) days, and subject to any applicable law, the
Party hereto that is not a party to such proceeding will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property with respect to the Program
(including the Technology File as defined above), and same, if not already in their possession, will be promptly delivered to them (i) upon their written request there for, unless the Party subject to such bankruptcy proceeding or a party
designated by such Party elects to continue to perform all of its obligations under this Agreement, or (ii) if not delivered under (i) above, following the final rejection of this Agreement in such bankruptcy proceeding by or on behalf of
the Party subject to such proceeding in accordance with applicable law, upon written request there for by the non-subject Party. 
  

	12	CONFIDENTIAL INFORMATION 

  

	 	12.1	Definition 

 In the course
of satisfying their obligations hereunder, it is anticipated that the Parties will have access to and/or learn confidential and/or proprietary information and/or trade secrets of the other Party. Confidential and/or proprietary information and
materials (“Confidential Information”) means any information that is provided to one Party (“Recipient”) by the other Party (“Discloser”) or accessed by the Recipient in connection with this Agreement (whether received
before or after the Commencement Date) and shall include, but are not limited to: (1) organizational structure, responsibilities and plans; (2) methods of business operations, processes and practices; (3) sales and financial data,
projections and plans; (4) customer, client and employee information; (5) business and marketing objectives, strategies and plans; (6) know-how, research and scientific and technological developments; (7) product information;
(8) any information marked or stamped or verbally designated as Confidential; (9) the terms of this Agreement and any related agreement; (10) information which by its nature is confidential; and (11) information the Recipient
knows or ought reasonably to know is confidential. The Discloser may disclose Confidential Information to the Recipient either: (a) in writing; (b) by delivery of items; (c) by access to information that may be contained in a data
base; (d) by verbal discussion and/or visual presentation; or (e) by any other means Discloser determines necessary. “Trade Secrets” shall be defined as information, without respect to form, belonging to the Discloser and
licensed by it, including information which: (i) derives economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by other persons or entities who can obtain economic value from
its disclosure or use; and (ii) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. 
  

	 	12.2	General Obligations 

  

	 	(a)	 Recipient agrees that any Confidential Information disclosed by Discloser under this Agreement shall be maintained as confidential and that Recipient
shall not disclose any Confidential Information to any third party, except as provided below, during the duration of this Agreement and for a period for [*] after the termination or expiration of this Agreement. Confidential Information
disclosed to Recipient by Discloser shall be used only for the purpose of performing Recipient’s obligations under this Agreement, and Recipient must seek prior written approval

  

 20 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
from Discloser for any vendors, contractors, subcontractors, and third parties that Recipient proposes to use to perform its obligations hereunder. Any such vendors, contractors, subcontractors,
and third parties must be bound by a confidential disclosure agreement approved by the Discloser and containing terms equivalent to those contained herein. 

  

	 	(b)	Nothing in this Clause 12.2 shall be construed to prevent Recipient from disclosing Confidential Information of the Discloser to its Affiliates and their
respective employees, officers, directors and professional advisors (for the purpose of seeking professional advice) on a “needs-to-know” basis, provided that Recipient ensures such Confidential Information is treated as confidential by
such Affiliates and their respective employees, officers, directors and professional advisors. 

  

	 	(c)	Recipient shall not have any obligation of confidentiality with respect to Confidential Information that is in the public domain by use and/or publication at the time
of Recipient’s receipt from Discloser or thereafter becomes publicly available through means other than disclosure by Recipient; was already in Recipient’s possession prior to receipt from Discloser; is properly obtained by Recipient from
a third party with a valid right to disclose such Confidential Information and such third party is not under any confidentiality obligation to Discloser; or is disclosed by Discloser to any third party without an obligation of confidentiality.

  

	 	(d)	Recipient may disclose Confidential Information to the extent required by law. In the event that disclosure of Confidential Information is required by law, Recipient
shall notify legal counsel for Discloser of such requirement within five (5) business days of learning of the disclosure requirement and shall allow Discloser an opportunity to oppose such process and seek a protective order.

  

	 	(e)	Merial may disclose its own Confidential Information and the Confidential Information of APP as required and necessary to the applicable regulatory agency, including
the U.S. FDA, in order to obtain Registration(s) of the Licensed Product(s); however, Confidential Information that is so disclosed shall remain Confidential Information for all other purposes. For clarity, notwithstanding anything to the contrary
in this Agreement, neither Party shall have the right to disclose Confidential Information belonging to the other Pary in any patent filings without the other Party’s prior written consent. 

  

	 	(f)	Upon the expiration or termination of this Agreement, any and all Confidential Information received by Recipient or in Recipient’s possession, custody or control
or the possession, custody or control of Recipient’s employees, officers, agents or contractors, including any documents generated or created by Recipient containing any Confidential Information, shall either be promptly returned or destroyed,
as certified by Recipient, except Recipient may retain in Recipient’s confidential legal files solely for record purposes one copy of any document created or generated by Recipient containing Confidential Information. 

 

	 	(g)	 Recipient shall treat as confidential and shall not disclose, publish or use (other than for purposes of this Agreement) and shall maintain as
confidential, any information which constitutes Discloser’s trade secrets (whether or not the trade secrets are in written or tangible form) for as long as they remain trade secrets

  

 21 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
under applicable law. 

  

	 	(h)	Neither Party will originate any publicity, news release, public comment or other public announcement, written or oral, whether to the press, to stockholders, or
otherwise, relating to this Agreement, without the written consent of the other Party, which consent shall not be unreasonably withheld or delayed, except for such announcement which, in accordance with the advice of legal counsel to the Party
making such announcement, is required by law or the regulations of the securities exchange on which such Party’s securities are traded, if any. The Party making any required announcement will, unless prohibited by law, give the other Party an
opportunity to review the form and content of such announcement and comment before it is made. Either party shall have the right to make such filings with governmental agencies, including the United States Securities and Exchange Commission, as to
the contents and existence of this Agreement as it shall reasonably deem necessary or appropriate. 

  

	 	(i)	Notwithstanding anything in this Agreement to the contrary, any previous Confidentiality Agreements between the Parties shall continue in full force pursuant to the
terms thereunder with respect to information exchanged between the Parties prior to the Effective Date. 

  

	13	REGISTRATION OF THE LICENSED PRODUCT IN THE TERRITORY 

  

	 	13.1	Ownership of Licensed Product Registration 

  

	 	(a)	Merial shall use Commercially Reasonable Efforts to obtain and maintain at its own cost and expense and in its own name all Registrations, and upon issuance, Merial
shall be the sole owner of such Licensed Product Registrations. 

  

	 	13.2	Additional Testing 

 Subject to the terms of Clause 7.4, in the event that there is a need to conduct tests or studies in addition to the clinical tests necessary for obtaining or maintaining a Registration for the Licensed Product(s) or subsequent to
obtaining Registration, any such activities will be performed by Merial at its own expense. 
  

	 	13.3	Contacts with the U.S. FDA and Other Regulatory Agencies 

  

	 	(a)	Merial exclusively shall deal with the U.S. FDA and any other regulatory agencies from which Merial seeks approval of the Licensed Product(s). 

 

	 	(b)	Each Party shall promptly notify the other Party of any and all inquiries received from the U.S. FDA and/or any other Regulatory Agency concerning the Technology and/or
Licensed Product(s) during the term of this Agreement, and it shall notify the other Party of any information it receives from any source regarding any threatened or pending action by a Regulatory Agency. Each Party shall promptly provide to the
other Party notice of and summary reports regarding of any communications and/or meetings with the U.S. FDA or other Regulatory Agencies. If the matter relates exclusively to the Licensed Product(s) in the Field, Merial shall determine in its sole
discretion the response, [*]. If the matter relates to the Technology but not its inclusion in the Licensed Product in the Field, APP shall determine in its sole discretion the response, [*]. 

  

 22 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	13.4	APP’s Cooperation to Obtain and Maintain Registration 

 APP acknowledges and agrees that it maintains, or will maintain in the future, certain information, including manufacturing know-how, that is necessary for the approval and maintenance of the Registration
of the Licensed Product(s) in the Field in the United States and elsewhere in the Territory, and APP agrees to share with Merial all such information within APP’s control necessary to obtain and maintain such Registration(s). 
  

	14	LICENSED PRODUCT BRANDING 

  

	 	14.1	APP Trademarks 

  

	 	(a)	APP grants to Merial a non-exclusive royalty-free license during the Term to use the APP Trademarks nominated by APP from time to time to brand, package, promote, and
advertise the Licensed Product(s) and to use in promotional and instructional materials produced by Merial for the Licensed Product(s). APP shall provide to Merial upon request a copy of the relevant APP Trademarks of a quality suitable for
reproduction. 

  

	 	(b)	Merial may only use such APP Trademarks with the prior approval of APP for each type of use or application, such approval not to be unreasonably withheld.

  

	 	(c)	When using an APP Trademark under this Clause 14.1, Merial must not allow the appearance of the APP Trade Mark to be altered in any way (other than proportional
size adjustment) without APP’s prior approval, such approval not to be unreasonably withheld. 

  

	 	(d)	Notwithstanding anything herein to the contrary, Merial shall not be required to use the APP Trademark to Exploit the Licensed Product(s) in the Field in the Territory.

  

	 	14.2	Merial Branding 

 Merial
may elect to brand the Licensed Product(s) sold in the Territory with a Merial brand name or trademark and will own all Intellectual Property Rights in such brand name or trademark. At no time during this Agreement or after the expiration or
termination hereof shall APP have any interest in or ownership of the Merial trademark or brand name selected by Merial to brand the Licensed Product(s) in the Territory. 
  

	15	DISPUTE RESOLUTION 

  

	 	15.1	Notice of Dispute 

  

	 	(a)	If a difference or dispute (together called a “Dispute”) between the Parties arises out of or relates to this agreement, either Party may give the
other party a written notice of dispute adequately identifying and providing details of the Dispute (“Notice of Dispute”). 

  

	 	(b)	Notwithstanding the existence of a Dispute, the Parties will, subject to this agreement, continue to perform their obligations under this agreement.

  

	 	15.2	Dispute Resolution 

 Once
a Notice of Dispute has been given under Clause 15.1, the Parties must

  

 23 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
take the steps required by this Clause 15.2 and use all reasonable endeavors to resolve the dispute by negotiating in good faith: 
  

	 	(a)	initially between the chief executive officers of each Party or their delegates, who must confer and endeavor to resolve the Dispute within fifteen (15) Business
Days, or such other period as they may agree. All aspects of every such conference, except the fact of its occurrence, will be confidential; and 

  

	 	(b)	if the Dispute is not resolved under Clause 15.2(a), then the chief executive officers or their delegates may refer the Dispute for resolution by mediation under
Clause 15.3. 

  

	 	15.3	Mediation 

  

	 	(a)	If the Parties agree to refer the Dispute for resolution by non-binding mediation, then the Parties agree to endeavor in good faith to settle the Dispute by mediation
before resorting to litigation. 

  

	 	(b)	The mediation will be conducted in Chicago, Illinois, before a mediator jointly selected by the Parties. If the Parties are unable to agree on the selection of the
mediator, the Parties agree that the American Arbitration Association shall select the mediator. 

  

	 	(c)	If the Dispute cannot be resolved within twenty (20) Business Days of commencement of mediation or such other period as the Parties agree, either Party may, after
notice in writing of not less than ten (10) Business Days to the other, commence legal proceedings in relation to that Dispute. 

  

	 	(d)	The Parties must bear equally the costs of the mediation, excluding each Party’s legal costs. 

  

	 	15.4	Exchange of Information 

 The Parties acknowledge that the purpose of any exchange of information or documents or the making of any offer of settlement pursuant to this clause is to attempt to settle the Dispute between the Parties. Neither Party may use any
information or documents obtained through the Dispute resolution process established by this Article 15 for any purpose other than an attempt to settle a Dispute between the Parties. 
  

	 	15.5	Legal Proceedings 

 Except
with respect to intellectual property matters, neither Party may commence legal proceedings, other than proceedings seeking urgent interlocutory relief, in respect of the Dispute without first complying with Clauses 15.1, 15.2 and
15.3. 
  

	16	REPRESENTATIONS AND WARRANTIES 

  

	 	16.1	Corporate Existence and Power 

  

	 	(a)	As of the Commencement Date, APP represents and warrants to Merial that it: 

  

	 	(i)	is a corporation duly organized, validly existing and in good standing under the laws of the state in which it is incorporated, and 

  

 24 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	(ii)	has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and is
contemplated in this Agreement, including, without limitation, the right to grant the licenses granted hereunder. 

  

	 	(b)	As of the Commencement Date, Merial represents and warrants to APP that it: 

  

	 	(i)	a company limited by shares registered in England and Wales and domesticated in Delaware, USA as Merial LLC, and 

  

	 	(ii)	has full corporate power and authority and the legal right to own and operate its property and assets and to carry on its business as it is now being conducted and is
contemplated in this Agreement, including, without limitation, the right to grant the licenses granted hereunder. 

  

	 	16.2	Authority 

 As of the
Commencement Date, each Party represents and warrants to the other that it: 
  

	 	(a)	has the corporate power and authority and the legal right to enter into this Agreement and perform its obligations hereunder; 

  

	 	(b)	has taken all necessary corporate action on its part required to authorize the execution and delivery of the Agreement and the performance of its obligations hereunder;
and 

  

	 	(c)	the Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party and is enforceable
against it in accordance with its terms. 

  

	 	16.3	Absence of Litigation 

 As
of the Commencement Date, Merial and APP each represent and warrant to each other that each is not aware of any pending or threatened litigation (and has not received any communication relating thereto) which alleges that the activities of Merial or
APP, with respect to the Technology, Patent, or Licensed Product, or otherwise related to this Agreement, have infringed or misappropriated, or that by conducting the activities as contemplated herein by APP or Merial would infringe or
misappropriate any Intellectual Property Rights of any other Person. 
  

	 	16.4	No Approvals or Consents Required 

 Except as otherwise described in this Agreement, each Party represents and warrants to the other that all necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained by such
Party in connection with entry into this Agreement have been obtained. 
  

	 	16.5	Patents; Prior Art 

 Except as each Party has otherwise advised the other Party in writing prior to the Commencement Date, each Party represents and warrants to the other Party that as of the Commencement Date, (a) to the best of its knowledge, it has
sufficient legal and/or

  

 25 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
beneficial title and ownership under its intellectual property rights necessary for it to fulfill its obligations under this Agreement; and (b) to the best of its knowledge, there is no
material unauthorized use, infringement, or misappropriation of any of its intellectual property rights by third parties relevant to the Program or other rights granted under this Agreement. As used herein, “intellectual property rights”
shall mean all patent rights, copyrights, trademarks, trade secrets, and confidential and/or proprietary chemical substances, technical information, data and assays necessary or useful to the Program. 
  

	 	16.6	No Conflict 

 Each Party
represents and warrants to the other that the execution and delivery of the Agreement by such Party and the performance of such Party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable law or
regulation or any provision of articles of incorporation or by laws of such Party in any material way and (b) do not conflict with, violate, or breach or constitute a default or require any consent under, any contractual obligation or court or
administrative order by which such Party is bound. 
  

	 	16.7	No Prior Licenses 

 APP
represents and warrants to Merial that prior to the Commencement Date, neither it nor any APP Affiliate has granted any licenses or covenants-not-to-sue to Third Parties with respect to the Licensed Product(s), including, the right to Exploit the
Licensed Product(s) in the Field in the Territory. 
  

	17	INDEMNITY 

  

	 	17.1	Indemnification by APP 

 APP hereby agrees to indemnify, hold harmless and defend Merial against any and all expenses, costs of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and
any amounts Merial becomes legally obligated to pay because of any third party claim or claims against it to the extent that such claim or claims (i) arise out of the breach or alleged breach of any representation or warranty by APP hereunder,
or (ii) are due to the negligence or misconduct of APP; provided that (a) Merial provides APP with prompt notice of any such claim and the exclusive ability to defend (with the reasonable cooperation of Merial) and settle any such claim
and (b) such indemnities shall not apply to the extent such claims are covered by Merial’s indemnity set forth in Clause 17.2 below. 
  

	 	17.2	Indemnification By Merial 

 Merial hereby agrees to indemnify, hold harmless and defend APP against any and all expenses, costs of defense (including without limitation attorneys’ fees, witness fees, damages, judgments, fines and amounts paid in settlement) and
any amounts APP becomes legally obligated to pay because of any third party claim or claims against it to the extent that such claim or claims (i) arise out of the breach or alleged breach of any representation or warranty by Merial hereunder,
(ii) are due to the negligence or misconduct of Merial, or (iii) arise out of the possession, manufacture, use, sale or administration of the Licensed Product(s) by Merial or Merial’s Affiliates or sublicensees; provided that
(a) APP provides Merial with prompt notice of any such claim and the exclusive ability to defend (with the reasonable cooperation of APP) or settle any such claim and (b) such indemnities shall not apply to the extent such claims are
covered by

  

 26 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 
APP’s indemnity set forth in Clause 17.1 above. 
  

	 	17.3	Mechanics 

 In the event
that the Parties cannot agree as to the application of Clauses 17.1 and 17.2 above to any particular loss or claim, the parties may conduct separate defenses of such claim. Each Party further reserves the right to claim indemnity from
the other in accordance with Clauses 17.1 and 17.2 above upon resolution of the underlying claim, notwithstanding the provisions of Clauses 17.1 and 17.2 above requiring the indemnified Party to tender to the indemnifying
party the exclusive ability to defend such claim or suit. 
  

	18	INSURANCE 

 Each Party
represents and warrants that it is covered and will continue to be covered by a comprehensive general liability insurance program which covers all of its own activities and obligations hereunder. Each Party shall provide the other Party with written
notice at least fifteen (15) days prior to any cancellation or material change in such insurance program. Each Party shall maintain such insurance program, or other program with comparable coverage, beyond the expiration or termination of this
Agreement during (i) the period that any Licensed Product is being commercially distributed or sold other than for the purpose of obtaining regulatory approvals by Merial or by a sublicensee, Affiliate or agent of Merial and (ii) a
commercially reasonable period thereafter. 
  

	19	NOTICES 

  

	 	19.1	General 

 Any notice or
other written communications required or permitted to be made or given hereunder may be made or given by either Party by fax communication to the fax number set forth below, and such notice shall be followed up by depositing the same in the mail,
certified delivery, return receipt requested, postage prepaid, and addressed to the mailing address set forth below. 
  

	 	19.2	Particulars for Delivery of Notices 

  

	 	(a)	The particulars for delivery of notices are initially: 

  

 27 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 APP 
 VP R&D 
 A.P. Pharma, Inc. 
 123 Saginaw Drive, 
 Redwood City, CA 94063 
 Fax: +1 650 365 9452 or +1 650 365 6490 
 Attention: Dr. John Barr 
 With a copy to: 
 Chief Executive Officer 
 A.P Pharma, Inc. 
 123 Saginaw Drive 
 Redwood City, CA 94063 
 Fax: +1 650 365 9452 or +1 650 365 6490 
 And a copy to: 
 Latham & Watkins LLP 
 140 Scott Drive 
 Menlo Park, CA 94025 
 Fax: +1 650 463 2600 
 Attention: Alan Mendelson 
 Merial 
 General Counsel 
 3239 Satellite Boulevard 
 Duluth, Georgia USA 30096 
 Fax: (678) 638-3960 
 With a copy to: 
 Global Head of R&D 
 3239 Satellite Boulevard 
 Duluth, Georgia USA 30096 
 Fax: (678) 638-3600 
 And for Intellectual Property Matters a copy to: 
 Global Head of IP 
 3239 Satellite Boulevard 
 Duluth, Georgia USA 30096 
 Fax: (678) 638-3350 
  

	 	(b)	Each Party may change its particulars for delivery of notices by written notice to the other Party. 

  

	 	19.3	After Hours Communications 

 If a communication is given: 
  

	 	(a)	after 5:00 p.m. in the place of receipt; or 

  

	 	(b)	 on a day which is a Saturday, Sunday, or bank or public or federal holiday in the

  

 28 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
place of receipt, 

 it is taken as having been given at
9:00 a.m. on the next day which is not a Saturday, Sunday, or bank or public or federal holiday in that place. 
  

	 	19.4	Process Service 

 Any
process or other document relating to litigation, administrative or mediation proceedings relating to this Agreement may be served by any method contemplated by this Article 19 or in accordance with any applicable law. 
  

	20	Force Majeure 

  

	 	(a)	For the purposes of this clause, “Force Majeure” means any circumstance beyond the reasonable direct or indirect control and without the fault or
negligence of the Party claiming Force Majeure, including any act of God, act of war, cyclone, fire, flood, explosion, storm or earthquake. 

  

	 	(b)	Delays in or failure of performance by a Party shall not constitute a breach of this agreement by that Party if and to the extent any delay or failure is caused by a
Force Majeure, provided the Party claiming Force Majeure: 

  

	 	(i)	notifies the other Party in writing within three (3) Business Days of the occurrence of the Force Majeure providing details of the Force Majeure and its
anticipated likely duration and effect; and 

  

	 	(ii)	uses its reasonable best endeavors to resume fulfilling its obligations as promptly as possible and provides the other Party with written notice within three
(3) Business Days of the cessation of the Force Majeure. 

  

	 	(c)	If a delay caused by Force Majeure continues for more than [*] days, either Party may terminate this agreement by giving thirty (30) days’ notice to
the other Party. 

  

	21	GENERAL 

  

	 	21.1	Legal Costs 

 Except as
expressly stated otherwise in this document, each Party must pay its own legal and other costs and expenses of negotiating, preparing, executing, and performing its obligations under this Agreement. 
  

	 	21.2	Amendment 

 This Agreement
may not be amended, replaced or varied, except in writing, signed by both Parties, and making reference to this Agreement. 
  

	 	21.3	Waiver and Exercise of Rights 

  

	 	(a)	A single or partial exercise or waiver by a Party of a right relating to this document does not prevent any other exercise of that right or the exercise of any other
right. 

  

 29 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	(b)	A Party is not liable for any loss, cost, or expense of any other Party caused or contributed to by the waiver, exercise, attempted exercise, failure to exercise or
delay in the exercise of a right. 

  

	 	21.4	Rights Cumulative 

 Except
as expressly stated otherwise in this document, the rights of a Party under this document are cumulative and are in addition to any other rights of that Party. 
  

	 	21.5	Further Steps 

 Each Party
must promptly do whatever any other Party reasonably requires of it to give effect to this document and to perform its obligations under it. 
  

	 	21.6	Governing Law 

 This
Agreement is governed by and is to be construed in accordance with the laws of the State of Delaware. 
  

	 	21.7	Assignment 

  

	 	(a)	A Party may not assign this Agreement or any right or obligation hereunder without the prior written consent of the other Party. Notwithstanding the foregoing, Merial
shall have the right to assign this Agreement to any of its Affiliates without prior consent from APP; APP shall have the right to receive any consideration due from Merial to APP under the Agreement, including royalties, to a third party without
prior consent from Merial; and either Party shall have the right to assign, without prior consent of the other Party, its rights and obligations under this Agreement to a successor to all or substantially all of its business or assets to which this
Agreement relates. 

  

	 	(b)	Any purported dealing in breach of this clause is of no effect. 

  

	 	21.8	Liability 

 An obligation
of two or more persons binds them separately and together. 
  

	 	21.9	Counterparts 

 This
document may consist of a number of counterparts and, if so, the counterparts taken together constitute one document. 
  

	 	21.10	Entire Understanding 

  

	 	(a)	 Any previous confidentiality agreements between the Parties hereto shall remain in full force and effect. Subject to the foregoing, this Agreement
contains the entire understanding between the Parties as to the subject matter hereof; provided, however, that (i) this Agreement shall not supersede the letter agreement between the parties dated July 17, 2009, which shall continue in
full force and effect as provided therein, and (ii) this Agreement shall not supersede the terms of the Research and Development Agreement effective January 22, 2007, as amended, between the parties as to activities conducted pursuant to
the POC Phase prior to the Effective Date, and such Research and Development Agreement shall continue in full force and effect to govern the

  

 30 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

	 	 
Parties’ rights and obligations with respect to the POC Phase as conducted thereunder. 

  

	 	(b)	All previous negotiations, understandings, representations, warranties, memoranda or commitments concerning the subject matter of this Agreement are merged in and
superseded by this Agreement and are of no effect. No Party is liable to any other Party in respect of those matters. 

  

	 	(c)	No oral explanation or information provided by any Party to another: 

  

	 	(i)	affects the meaning or interpretation of this document; or 

  

	 	(ii)	constitutes any collateral agreement, warranty or understanding between any of the Parties. 

  

	 	21.11	Relationship of Parties 

 This document is not intended to create a partnership, joint venture, employment, or agency relationship between the Parties. 
  

	 	21.12	Ethical Business Practices 

  

	 	(a)	The Parties shall adhere to business practices in connection with this Agreement which are in accordance with the letter and spirit of applicable laws and ethical
principles. Each Party represents and warrants to the other that all transactions will be accurately reflected in their respective books and records, and that no funds or other assets will be paid directly or indirectly to government officials (or
persons acting on their behalf) for the purpose of influencing government decisions or actions. Violation of this policy may result in the immediate termination of this Agreement. 

  

	 	(b)	No employee of Merial will have authority to give any direction, written or oral, relating to the making of any commitment by APP or its agents to any third party in
violation of the terms of this Clause 21.12. 

 IN WITNESS THEREOF, the authorized representatives of the Parties hereto
have executed this Agreement effective on the day and the year first set forth above. 
  

					
	A.P. PHARMA INC.	 		  	MERIAL LIMITED:
			
	 /s/ Ronald Prentki
	 		  	 /s/ Jose G. R. Barella

	(Signature)	 		  	(Signature)
			
	Ronald Prentki	 		  	Jose G. R. Barella
	Name (print)	 		  	Name (print)
			
	President and CEO	 		  	Executive Chairman
	Title	 		  	Title

  

 31 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 EXHIBIT A 
 Relevant Intellectual Property 
 Patents

 [*] 
  

 1 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 EXHIBIT B 
 RESEARCH PROGRAM 
 [*] 
  

 2 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 Exhibit C 
 [*] 
  

 3 
  

	[*]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions.General Release and Settlement Agreement - RightNow Technologies, Inc.

 Exhibit 10.4 
 GENERAL RELEASE & SETTLEMENT AGREEMENT 
  

			
	PARTIES:	  	RightNow Technologies, Inc. (“RightNow”); and KANA Software Inc. (“KANA”).
		
	DESCRIPTION OF CLAIMS:	  	The claims and counterclaims set forth, or which could have been set forth, in RightNow Technologies, Inc. v. KANA Software, Inc., et al, Cause No. DV-07-42BX, Montana
Eighteenth Judicial District Court, Gallatin County (collectively, the “Claims”).
		
	SUM OF SETTLEMENT:	  	$1,000,000.00

 1. Release 
 (a) KANA will pay to RightNow the Sum of Settlement as follows: 
  

	 	(i)	$100,000.00 within 10 days of the execution of this General Release & Settlement Agreement by the parties, but no later than October 25, 2009; and

  

	 	(ii)	$100,000.00 per quarter for nine (9) consecutive quarters, without interest, as set forth in the table below. 

  

											
	 Payment
	    	 Quarter
	    	 Date Payment is Due
	    	Payment
Amount	    	Balance Due
		    		    		    			    	$	1,000,000.00
	 1
	    	N/A	    	10 days after execution	    	$	100,000.00	    	$	900,000.00
	 2
	    	1st Quarter 2010	    	February 16, 2010	    	$	100,000.00	    	$	800,000.00
	 3
	    	2nd Quarter 2010	    	May 17, 2010	    	$	100,000.00	    	$	700,000.00
	 4
	    	3rd Quarter 2010	    	August 16, 2010	    	$	100,000.00	    	$	600,000.00
	 5
	    	4th Quarter 2010	    	November 15, 2010	    	$	100,000.00	    	$	500,000.00
	 6
	    	1st Quarter 2011	    	February 14, 2011	    	$	100,000.00	    	$	400,000.00
	 7
	    	2nd Quarter 2011	    	May 16, 2011	    	$	100,000.00	    	$	300,000.00
	 8
	    	3rd Quarter 2011	    	August 15, 2011	    	$	100,000.00	    	$	200,000.00
	 9
	    	4th Quarter 2011	    	November 14, 2011	    	$	100,000.00	    	$	100,000.00
	 10
	    	1st Quarter 2012	    	February 14, 2012	    	$	100,000.00	    	$	0

 If KANA fails to make any payment on or before the due date, it shall have 10 days to cure its default. If
KANA fails to cure its default within 10 days, RightNow may, by notice, cause acceleration of the outstanding Balance Due, which shall become immediately due and payable in full to RightNow and accrue interest at 10% per annum from the date of
acceleration. By way of example only, if KANA fails to pay RightNow $100,000.00 by February 14, 2011, and fails to cure that default by February 24, 2011, then RightNow may accelerate the Balance Due of $500,000.00, with interest at
10% per annum from the date or acceleration. 
 In the event of a “Change in Control” (defined below) of KANA, the outstanding
Balance Due will become due and payable in full to RightNow within ten (10) business days of the closing of the transaction that triggers the “Change in Control”. If KANA fails to make such payment by the due date, interest on the
outstanding Balance Due shall accrue at 10% per annum. By way of example only, if a Change in Control of KANA occurs on January 1, 2011, then the remaining indebtedness of $500,000.00 will be due and payable in full to RightNow no later
than January 14, 2011. 
 “Change in Control” shall mean a change in ownership or control of KANA effected through any of the
following transactions: 
  

	 	(1)	a merger, consolidation or other reorganization unless securities representing more than 65% of the total combined voting power of the voting securities of the
successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the KANA’s outstanding voting securities immediately prior to such
transaction; 

  

	 	(2)	the sale, transfer or other disposition of all or substantially all of KANA’s assets; 

  

	 	(3)	the acquisition, directly or indirectly by any person or related group of persons (other than KANA or a person that directly or indirectly controls, is controlled by,
or is under common control with KANA), of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing 35% or more of the total combined voting power of KANA’s outstanding securities pursuant to a tender
or exchange offer made directly to KANA’s stockholders; or 

  

	 	(4)	a change in the composition of the Board of Directors over a period of 36 consecutive months or less such that a majority of the directors ceases, by reason of one or
more contested elections for directorship, to be comprised of individuals who either (i) have been directors continuously since the beginning of such period or (ii) have been elected or nominated for election as directors during such
period by at least a majority of the directors described in clause (i) who were still in office at the time the Board of Directors approved such election or nomination. 

 (b) To secure KANA’s payment obligations under this General Release & Settlement Agreement, KANA hereby grants to RightNow a subordinated
security interest in all of KANA’s personal property, whether now owned or hereafter acquired, including without limitation the property as set forth on Exhibit A attached hereto, and all products, proceeds and

 
insurance proceeds of the foregoing. This security interest will terminate and all liens shall be released automatically and without further action of the parties upon payment in full to RightNow
of the amounts set forth in Paragraph 1, above, and RightNow agrees that upon payment in full to RightNow of such amounts, RightNow will promptly execute and file, and hereby authorizes KANA, its officers and directors, attorneys or agents to file
following such payment in full, any releases and lien termination statements that may be required or desirable in order to evidence such termination and release. 
 (c) In consideration for payment of the Sum of Settlement and the mutual promises contained herein, each party fully and forever releases and discharges the others and their respective successors,
assigns, agents, partners, employees and attorneys from any and all actions, claims, causes of action, demands, or expenses for damages or injuries, whether asserted or unasserted, known or unknown, foreseen or unforeseen, arising out of the
described Claims, except that the obligations of RightNow and KANA under this General Release and Settlement Agreement are not released, but are enforceable according to the terms of this General Release & Settlement Agreement. 

2. Future Damages 
 Inasmuch as
the injuries, damages, and losses resulting from the events described herein may not be fully known and may be more numerous or more serious than it is now understood or expected, each party agrees, as a further consideration of this agreement, that
this General Release & Settlement Agreement applies to any and all injuries, damages and losses resulting from the Claims described herein, even though now unanticipated, unexpected and unknown, as well as any and all injuries, damages and
losses which have already developed and which are now known or anticipated. 
 3. No Admission of Liability 
 It is understood that the Sum of Settlement and the mutual promises contained herein are accepted as the sole consideration for full satisfaction and accord
to compromise a disputed claim, and that neither the payment of the Sum of Settlement by KANA, nor the mutual promises contained herein, nor the negotiations for settlement shall be considered as an admission of liability. 
 4. Stipulation for Dismissal With Prejudice 
 RightNow stipulates and agrees that upon: (A) execution of this General Release & Settlement Agreement, and the General Release & Settlement Agreement by and between RightNow, KANA, Christine Franz, Tim Wolfe, Jake
McElroy and Chris Kelly; and (B) payment by KANA of the $100,000.00 due to RightNow under Paragraph 1(a)(i), RightNow’s attorney of record shall dismiss with prejudice, as fully settled upon the merits, the above-described civil action.
Each party shall pay its, his or her costs, expenses and attorneys’ fees. Notwithstanding the foregoing, mediation fees will be paid equally by RightNow and KANA. This General Release & Settlement Agreement is contingent upon the full
execution of the General Release & Settlement Agreement by and between KANA, RightNow, Christine Franz, Tim Wolfe, Jake McElroy and Chris Kelly. 

 5. No Intention of Filing for Bankruptcy or Increase Borrowings from Banks 
 KANA represents that it has not consulted counsel regarding bankruptcy and that it has no intention of filing for bankruptcy protection within 90 days of the
date of its first payment to RightNow hereunder. In addition, KANA represents and agrees that it does not intend to borrow additional amounts from banks other than Agility Capital LLC and Bridge Bank N.A. and it will not increase its borrowings from
such banks above the current combined maximum borrowing amount of $6,000,000 (US Six Million Dollars). 
 6. Disclaimer

 Each party has carefully read the foregoing, discussed its legal effect with its, his or her attorney, understands the contents thereof,
and signs the same of its, his or her own free will and accord. 
 This General Release & Settlement Agreement shall be binding upon
each party’s successors, assigns, agents, partners, employees and attorneys. 
 7. Confidential 
 The parties acknowledge that the amount and terms of this settlement are to be confidential and shall not be publicly disclosed by them or their
representatives, except a party may disclose such information (1) as its counsel may advise it is required to disclose under applicable laws and regulations, or (2) as may be required in connection with disputes pertaining to insurance
coverage of the Claims involved here, or (3) as otherwise required by an order of court of competent jurisdiction. The parties further agree that the court may approve this settlement and order its conditions to be performed. 
 8. Notice 
 Any notice required or
permitted to be given pursuant to this General Release & Settlement Agreement shall be deemed to have been given when delivered in person or deposited in the U.S. mail, certified, return receipt requested, postage prepaid, or delivered to a
nationally recognized overnight delivery service, addressed as follows: 
 To RightNow: 
 c/o Goetz, Gallik & Baldwin P.C. 
 35 North Grand 
 P.O. Box 6580 
 Bozeman, MT 59771-6580 

 To KANA: 
 Will Bose, General Counsel 
 Kana Software, Inc. 
 181 Constitution Drive 
 Menlo Park, CA 94025 
 With copy to: 
 John H. Tarlow, Esq 
 Tarlow Stonecipher & Steele PLLC 
 1705 West College Street 
 Bozeman, MT 59715-4913 
 Any
address for notice may be changed by written notice. 
 9. Governing Law; Jurisdiction & Venue 
 This General Release & Settlement Agreement shall be governed by and construed in accordance with the laws of the State of Montana without regard to
its conflict of laws principles. Any action brought in connection with this Agreement or the transactions contemplated by this Agreement must be brought in a court of competent jurisdiction sitting in Gallatin County, Montana. The parties agree that
jurisdiction and venue in such courts is proper and they waive any defense of lack of personal jurisdiction or inappropriate or inconvenient venue. 
 10. Counterparts 
 This General Release & Settlement Agreement may be executed in one or more counterparts, each
of which shall for all purposes be deemed to be an original and all of which together shall constitute the same instrument. 
 DATED this      day of             , 2009. 

	
	CAUTION: READ BEFORE SIGNING!
	
	 /s/ ALAN RASSABY

	Alan Rassaby
	RightNow Technologies, Inc.

  

			
	STATE OF MONTANA	  	)
		  	) ss
	County of GALLATIN)	  	

 ACKNOWLEDGED before me this 16th day of October, 2009, by
                            . 
  

			
		  	 /s/ SANDRA L. FISCHER

		  	SANDRA L. FISCHER
		  	Notary Public, State of Montana
	(NOTARIAL SEAL)	  	County of GALLATIN
		  	My commission expires: March 29/2011

  

	
	APPROVED BY:
	
	 /s/ JAMES H. GOETZ

	James H. Goetz
	Attorney for RightNow Technologies, Inc.

	
	CAUTION: READ BEFORE SIGNING!
	
	 /s/ WILLIAM A. BOSE 

	WILLIAM A. BOSE
	(Print name)
	KANA Software, Inc.

  

			
	STATE OF MONTANA	 	)
		 	) ss
	County of
                            	 	)

 ACKNOWLEDGED before me this
            , 2009, by
                            . 
  

			
		  	  

		  	  

		  	Notary Public, State of Montana
	(NOTARIAL SEAL)	  	County of
                            
		  	My commission expires:             /20    
		
		  	[SEE ATTACHED]

  

	
	APPROVED BY:
	
	 /s/ J.H. TARLOW

	  

	(print name)
	Attorney for KANA Software, Inc.

 CALIFORNIA ALL-PURPOSE 
 CERTIFICATE OF ACKNOLWEDGMENT 
  

			
	STATE OF CALIFORNIA	  	)
		  	) ss
	County of SAN MATEO	  	)

 On OCTOBER 14, 2009 before me, M. HALLER, N.P., personally appeared WILLIAM A. BOSE
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by
his/her/their signature(s) on the instrument the person(s) or the entity up on which the person(s) acted, executed the instrument. 
 I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct. 
 WITNESS my hand and official seal. 
  

					
	 /s/ M. HALLER
	  		  	[Notary Seal]
	Signature of Notary Public

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]